Experiment 341546

Worktypes

PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODEANTIFERTILITYCOMPLETE SYNTHESIS REPORTEDSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE

Compounds isolated

LYSERGIC ACID,DIHYDRO: AZIDE*LYSERGATE,ISO: DIHYDRO:CHANOCLAVINELYSERGINELYSERGOL,ISO:ELYMOCLAVINE CARBAMATE*ERGOCORNINECHANOCLAVINE I,N-METHYL-DEOXY:*LYSERGOL II,DIHYDRO:ELYMOCLAVINE-O-ACETATE*ELYMOCLAVINE BENZOATE*ELYMOCLAVINE PYRIDINIUM TOSYLATE*CHANOCLAVINE I,N-METHYL:*AGROCLAVINEERGOLINE,6-METHYL-8-AMINO:*ERGOLINE,9: 6-METHYL-8-ACETOXY-METHYLENE:*ELYMOCLAVINEFUMIGACLAVINE BLYSERGENEELYMOCLAVINE-BETA-D-FRUCTOSIDELYSERGINE,ISO:ELYMOCLAVINE-N-OXIDE*ELYMOCLAVINE,DIHYDRO:

Details

PropertyValue
Pharmacology
PROLACTIN INHIBITION
Administration routeIP
OrganismEmpty organism
CitationCASSADY,JM: LI,GS: SPITZNER,EB: FLOSS,HG:. (1974). ERGOT ALKALOIDS. ERGOLINES AND RELATED COMPOUNDS AS INHIBITORS OF PROLACTIN RELEASE.. 17()
Amount utilized
Compound isolated
DiseasePRETREATMENT WITH RESERPINE(2 MG,IP)18 HR BEFORE
Dose amount50.0 MCG
Number1
Qualitative resultACTIVE
AnimalRAT
Per unitKG
Dose expressionDOSE
GenderMALE